Special Issues | Value-Based Cancer Care

All previous special issues and supplements of Value-Based Cancer Care are available here. Browse the digital archive below or use the search page to find a specific article you're looking for.

Highlights from the Latest Special Issue:

2022 Year in Review - Multiple Myeloma

Multiple Myeloma Year in Review Introduction

Addition of ASCT to Triplet Induction and Lenalidomide Maintenance to Progression: Results from the DETERMINATION Trial

Daratumumab + Cyclophosphamide, Bortezomib, and Dexamethasone Induction Followed by Daratumumab Maintenance Achieved Durable Responses in Patients with RRMM and NDMM

2022

2022 Year in Review - Multiple Myeloma

2022 Year in Review - Multiple Myeloma

Faculty Perspectives: Optimizing Clinical Outcomes and Value-Based Management in Multiple Myeloma—The Role of Isatuximab

Faculty Perspectives: Optimizing Clinical Outcomes and Value-Based Management in Multiple Myeloma—The Role of Isatuximab

$Interview With the Innovators Current Approach to the Disease Journey of Patients with Relapsed or Refractory Follicular Lymphoma: Focus on the Key Manifestations, Risk Stratification, and Management Patterns$

Interview With the Innovators Current Approach to the Disease Journey of Patients with Relapsed or Refractory Follicular Lymphoma: Focus on the Key Manifestations, Risk Stratification, and Management Patterns

Faculty Perspectives: The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management

Faculty Perspectives: The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management

2021

MOA magnifier: The Important Role of YERVOY® (ipilimumab) in Combination with OPDIVO® (nivolumab)

MOA magnifier: The Important Role of YERVOY® (ipilimumab) in Combination with OPDIVO® (nivolumab)

Faculty Perspectives: Preventing and Managing Skeletal-Related Events in Cancer Patients with Bone Metastases and Multiple Myeloma

Faculty Perspectives: Preventing and Managing Skeletal-Related Events in Cancer Patients with Bone Metastases and Multiple Myeloma

2020

Managing CCA in the Setting of COVID-19

Managing CCA in the Setting of COVID-19

2019

December 2019 Highlights from the First Annual Cholangiocarcinoma Summit

December 2019 Highlights from the First Annual Cholangiocarcinoma Summit

2019 Fourth Annual Oncology Guide to New FDA Approvals

2019 Fourth Annual Oncology Guide to New FDA Approvals

2018

2018 Third Annual Oncology Guide to New FDA Approvals

2018 Third Annual Oncology Guide to New FDA Approvals

Mechanism of Pathway: Considerations of Cytogenetic and Molecular Mutation Status for Patients with Acute Myeloid Leukemia: A Deeper Look at the Role of Diagnosticand Ongoing Testing Across the Care Continuum

Mechanism of Pathway: Considerations of Cytogenetic and Molecular Mutation Status for Patients with Acute Myeloid Leukemia: A Deeper Look at the Role of Diagnosticand Ongoing Testing Across the Care Continuum

2017

June 2017, Vol 8, No 3, Supplement 2: The Evolution of Chemotherapy-Induced Nausea and Vomiting Management: Challenges and Opportunities

June 2017, Vol 8, No 3, Supplement 2: The Evolution of Chemotherapy-Induced Nausea and Vomiting Management: Challenges and Opportunities

Front-Line Treatment of Patients with Advanced Hodgkin Lymphoma

Front-Line Treatment of Patients with Advanced Hodgkin Lymphoma

February 2017, Vol 8, No 1, Supplement 1: Balancing Innovation and Value in Cancer Care: Spotlight on Non-Small-Cell Lung Cancer Treatment

February 2017, Vol 8, No 1, Supplement 1: Balancing Innovation and Value in Cancer Care: Spotlight on Non-Small-Cell Lung Cancer Treatment

2016

Highlights from Best Practices in Lung Cancer Navigation Summit

Highlights from Best Practices in Lung Cancer Navigation Summit

Consolidation Therapy After ASCT in Hodgkin Lymphoma: Why and Who to Treat

Consolidation Therapy After ASCT in Hodgkin Lymphoma: Why and Who to Treat

Mechanism of Action Magnifier – 2016 Desk Reference

Mechanism of Action Magnifier – 2016 Desk Reference

Mechanism of Action: Novel Mechanisms in Lung Cancer

Mechanism of Action: Novel Mechanisms in Lung Cancer

2015

Dx Profiler: Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?

Dx Profiler: Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?

Mechanism of Pathway: Phosphatidylserine, an Immune-Modulating Checkpoint, Ushers in the Next Wave of Immuno-Oncology Targets

Mechanism of Pathway: Phosphatidylserine, an Immune-Modulating Checkpoint, Ushers in the Next Wave of Immuno-Oncology Targets

2014

Mechanism of Action: Novel Mechanisms in CINV Treatment

Mechanism of Action: Novel Mechanisms in CINV Treatment

Mechanism of Pathway: The Promise of PD-1 Pathway Blockade in the Treatment of Metastatic Cancer

Mechanism of Pathway: The Promise of PD-1 Pathway Blockade in the Treatment of Metastatic Cancer

2013

Mechanism of Action: Key Advances in Hematology Oncology

Mechanism of Action: Key Advances in Hematology Oncology

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

VBCC Print Edition

VBCC Weekly e‑Newsletter

I have reviewed and consent to the terms of VBCC's Privacy Policy, and VBCC has my permission to retain my information in its database, and to forward pertinent communications to me.